The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Impacts of the MURANO study for future CLL treatment
Data from the Phase III MURANO study (NCT02005471) is a hot topic in the field of hematological oncology. The study evaluated the use of venetoclax plus rituximab vs. standard chemoimmunotherapy (bendamustine plus rituximab) in relapsed/refractory chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the study and forecasts how she sees the results of this trial shaping CLL treatment moving forwards.
